<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns="http://purl.org/rss/1.0/" xmlns:dc="http://purl.org/dc/elements/1.1/">
  <channel rdf:about="https://www.um.edu.mt/library/oar/handle/123456789/32252">
    <title>OAR@UM Collection:</title>
    <link>https://www.um.edu.mt/library/oar/handle/123456789/32252</link>
    <description />
    <items>
      <rdf:Seq>
        <rdf:li rdf:resource="https://www.um.edu.mt/library/oar/handle/123456789/42774" />
      </rdf:Seq>
    </items>
    <dc:date>2026-04-14T13:25:15Z</dc:date>
  </channel>
  <item rdf:about="https://www.um.edu.mt/library/oar/handle/123456789/42774">
    <title>Pharmacogenetic aspects of thiopurine methyltransferase in Maltese individuals.</title>
    <link>https://www.um.edu.mt/library/oar/handle/123456789/42774</link>
    <description>Title: Pharmacogenetic aspects of thiopurine methyltransferase in Maltese individuals.
Abstract: Thiopurine methyltransferase (TPMT) is an important enzyme for the metabolism of&#xD;
thiopurine drugs, and pharmacogenetic variability has been associated with serious adverse&#xD;
effects in treated patients. There is currently no information on TMPT gene variants in the&#xD;
Maltese population. The aims of this project were to (i) identify the frequencies of the&#xD;
clinically relevant alleles *2, *3B and *3C and (ii) screen the TPMT gene promoter for novel&#xD;
variants.&#xD;
DNA was obtained from patients suffering from Crohn's disease, and from anonymous&#xD;
random samples maintained at the Malta Biobank. Genotyping and promoter screening were&#xD;
carried out using PCR-RFLP, tetraprimer ARMS-PCR and Sanger sequencing. Assays were&#xD;
designed and optimized accordingly. Where necessary, bioinformatic tools were used for&#xD;
assay design and analysis of results. We identified the following allelic frequencies:&#xD;
TPMT*2: 0% (n=390) including both Crohn's and Biobank cord blood samples, TPMT*3B:&#xD;
(n=390) of which 41190 or 2.1 % of Crohn's patients' samples and 11200 or 0.5% Biobank&#xD;
cord blood samples, TPMT*3C: (n=856) of which 11172 or 0.6% of Crohn's patients'&#xD;
samples and 3/684 or 0.4% Biobank cord blood samples. Promoter sequencing (n=126&#xD;
chromosomes) revealed 3 SNPs (4567T&gt;A, 4621T&gt;A, 4793A&gt;T) and 5 different&#xD;
homozygous or heterozygous deletions of 17 or 34bp starting at different points between&#xD;
positions 4989-5023 (cumulative allelic frequency 36.9%, n=138)(NCBI Accession&#xD;
NG_012137.2). Two of these deletions were tandem repeats (VNTRs), while another deletion&#xD;
was in incomplete VNTR due to two mismatches. We also identified a hypervariable region&#xD;
terminating approximately 40bp upstream of the transcriptional start site (TSS) having&#xD;
multiple heterozygous SNPs that could not be electronically deconvoluted to indel variants.&#xD;
&#xD;
TPMT pharmacogene allelic frequencies are comparable to international reported values. The&#xD;
identified promoter variability could potentially confer important transcriptional regulatory&#xD;
influences, especially due to its TSS proximity. Further molecular and clinical studies are&#xD;
required to investigate this.
Description: M.SC.PHARMACOLOGY</description>
    <dc:date>2015-01-01T00:00:00Z</dc:date>
  </item>
</rdf:RDF>

